ADGRD1 and glioblastoma: Trials of immune checkpoint inhibitors, which are agnostic to specific antigens, have so far shown limited efficacy in GBM, with very few exceptions.24 We therefore postulate that GPR133 may present an opportunity for targeted immune therapies.